起立性低血圧治療薬市場- 世界の産業規模、シェア、動向、機会、予測、製品タイプ別、診断テストタイプ別、エンドユーザー別、地域別、競合別、2020-2030年

世界の起立性低血圧治療薬市場は、2024年に5億4,226万米ドルと評価され、2030年までCAGR 8.26％で成長すると予測されています。

起立性低血圧（姿勢低血圧）は、起立時に血圧が急激に低下し、めまい、失神、疲労などの症状を引き起こします。この症状は一過性のことが多いが、特に高齢者や高血圧患者では、より深刻な基礎的健康問題を示すこともあります。同市場は、特に高齢化社会における意識の高まりと診断能力の向上から利益を得ています。動的血圧モニタリングなどの臨床ツールや診断プロトコルの革新により、タイムリーな発見と治療が容易になっています。さらに、特に発展途上地域において、高齢者や高血圧患者における起立性低血圧の有病率に対する関心が高まっており、患者の転帰を改善し心血管リスクを低減することを目的とした効果的な医薬品治療に対する需要が高まっています。

市場促進要因

医療診断の進歩

主な市場課題

併存疾患と複雑な患者プロファイル

主要市場動向

神経原性起立性低血圧（nOH）フォーカス

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の起立性低血圧治療薬市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 製品別（ドロキシドパ、フルドロコルチゾン、インドメタシン、ミドドリン塩酸塩、NSAIDs、ピリドスチグミン）
  • 診断検査の種類別（血液検査、心電図、心エコー検査、ストレステスト）
  • エンドユーザー別（外来手術センター、診断センター、病院・診療所）
  • 地域別
  • 企業別（2024）
• 市場マップ

第6章 アジア太平洋地域の起立性低血圧治療薬市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • オーストラリア
  • 日本
  • 韓国

第7章 欧州の起立性低血圧治療薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • スペイン
  • イタリア
  • 英国

第8章 北米の起立性低血圧治療薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第9章 南米の起立性低血圧治療薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの起立性低血圧治療薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第13章 世界の起立性低血圧治療薬市場：SWOT分析

第14章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第15章 PESTEL分析

第16章 競合情勢

• Mylan N.V.
• Upsher-Smith Laboratories, LLC
• Chelsea Therapeutics International, Ltd
• Amgen Inc
• F. Hoffmann-La Roche Ltd
• Apotex Inc
• Pfizer Inc.
• Novartis AG
• H. Lundbeck A/S
• Amneal Pharmaceuticals LLC

第17章 戦略的提言

第18章 調査会社について・免責事項

The Global Orthostatic Hypotension Drugs Market was valued at USD 542.26 million in 2024 and is projected to grow at a CAGR of 8.26% through 2030. Orthostatic hypotension, or postural hypotension, involves a sudden drop in blood pressure upon standing, leading to symptoms such as dizziness, fainting, and fatigue. While often transient, the condition can also indicate more serious underlying health issues, especially in older or hypertensive individuals. The market benefits from growing awareness, especially among aging populations, and improved diagnostic capabilities. Innovations in clinical tools and diagnostic protocols-such as dynamic blood pressure monitoring-are facilitating timely detection and treatment. Additionally, rising attention to orthostatic hypotension's prevalence among elderly and hypertensive patients, particularly in developing regions, is spurring demand for effective pharmaceutical therapies aimed at improving patient outcomes and reducing cardiovascular risk.

Key Market Drivers

Advancements in Medical Diagnostics

Medical diagnostics have seen transformative progress, significantly influencing the management of orthostatic hypotension. Advanced molecular tools such as PCR, next-generation sequencing, and gene profiling now enable precise disease detection and characterization. Liquid biopsies offer a non-invasive method for monitoring disease biomarkers, aiding early diagnosis and treatment response. Additionally, point-of-care devices have become more efficient, providing rapid results critical for conditions like blood pressure abnormalities. Imaging advancements-including MRI, CT, and PET-further improve disease visualization and understanding. Artificial intelligence is increasingly applied to analyze complex datasets, supporting diagnostic accuracy and treatment planning. Omics-based biomarker discovery is fostering new diagnostic tests for cardiovascular and neurodegenerative diseases. Notably, a 2024 statement by the American Heart Association emphasized improved diagnosis and management strategies for orthostatic hypotension in hypertensive patients, highlighting the growing clinical focus on this condition and the need for targeted therapies to enhance patient outcomes

Key Market Challenges

Comorbidities and Complex Patient Profiles

Managing orthostatic hypotension becomes increasingly difficult in patients with multiple coexisting conditions such as diabetes, hypertension, or cardiovascular disease. Many of these individuals are on complex medication regimens, increasing the risk of adverse drug interactions and complicating treatment decisions. Polypharmacy often undermines the effectiveness of orthostatic hypotension drugs and raises safety concerns. Customized treatment approaches are necessary to address each patient's unique health profile, which may demand frequent monitoring and ongoing adjustments to therapy. Additionally, patients with overlapping conditions like neurodegenerative disorders face an elevated risk of falls, requiring holistic care strategies. Understanding the complex interplay between various diseases and their impact on blood pressure regulation is vital to delivering effective and safe treatment solutions.

Key Market Trends

Neurogenic Orthostatic Hypotension (nOH) Focus

There is growing clinical and commercial interest in neurogenic orthostatic hypotension (nOH) as a distinct subset of the broader condition. Common in patients with neurological disorders, nOH is increasingly recognized due to improved diagnostic awareness and specialized testing. This subtype, typically involving impaired norepinephrine release, has prompted the development of targeted therapies aimed at improving blood pressure stability. Ongoing clinical trials are evaluating nOH-specific treatments, contributing to a robust pipeline of potential new therapies. Patient advocacy groups and neurological foundations are helping raise awareness and accelerate research in this space. Personalized care strategies are being adopted to address the unique clinical needs of nOH patients. Furthermore, diagnostic advances-such as autonomic function testing-are enhancing accuracy and supporting precision treatment. Pharmaceutical companies are investing in innovative drug classes, including norepinephrine prodrugs and reuptake inhibitors, to meet the specific demands of this growing patient population.

Key Market Players

• Mylan N.V.
• Upsher-Smith Laboratories, LLC
• Chelsea Therapeutics International, Ltd
• Amgen Inc.
• F. Hoffmann-La Roche Ltd
• Apotex Inc
• Pfizer Inc.
• Novartis AG
• H. Lundbeck A/S
• Amneal Pharmaceuticals LLC

Report Scope:

In this report, the Global Orthostatic Hypotension Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Orthostatic Hypotension Drugs Market, By Product:

• Droxidopa
• Fludrocortisone
• Indomethacin
• Midodrine Hydrochloride
• NSAIDs
• Pyridostigmine

Orthostatic Hypotension Drugs Market, By Diagnostics Test Type:

• Blood Tests
• ECG
• Echocardiogram
• Stress Test

Orthostatic Hypotension Drugs Market, By End-User:

• Ambulatory Surgical Centers
• Clinics & Hospitals
• Diagnostic Centers

Orthostatic Hypotension Drugs Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
• Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Orthostatic Hypotension Drugs Market.

Available Customizations:

Global Orthostatic Hypotension Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Orthostatic Hypotension Drugs Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Droxidopa, Fludrocortisone, Indomethacin, Midodrine Hydrochloride, NSAIDs, Pyridostigmine)
  • 5.2.2. By Diagnostics Test Type (Blood Tests, ECG, Echocardiogram, Stress Test)
  • 5.2.3. By End User (Ambulatory Surgical Centers, Diagnostic Centers, Hospitals & Clinics)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. Asia Pacific Orthostatic Hypotension Drugs Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Diagnostics Test Type
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. Asia Pacific: Country Analysis
  • 6.3.1. China Orthostatic Hypotension Drugs Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Diagnostics Test Type
      • 6.3.1.2.3. By End User
  • 6.3.2. India Orthostatic Hypotension Drugs Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Diagnostics Test Type
      • 6.3.2.2.3. By End User
  • 6.3.3. Australia Orthostatic Hypotension Drugs Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Diagnostics Test Type
      • 6.3.3.2.3. By End User
  • 6.3.4. Japan Orthostatic Hypotension Drugs Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Product
      • 6.3.4.2.2. By Diagnostics Test Type
      • 6.3.4.2.3. By End User
  • 6.3.5. South Korea Orthostatic Hypotension Drugs Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Product
      • 6.3.5.2.2. By Diagnostics Test Type
      • 6.3.5.2.3. By End User

7. Europe Orthostatic Hypotension Drugs Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Diagnostics Test Type
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Orthostatic Hypotension Drugs Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Diagnostics Test Type
      • 7.3.1.2.3. By End User
  • 7.3.2. Germany Orthostatic Hypotension Drugs Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Diagnostics Test Type
      • 7.3.2.2.3. By End User
  • 7.3.3. Spain Orthostatic Hypotension Drugs Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Diagnostics Test Type
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Orthostatic Hypotension Drugs Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Diagnostics Test Type
      • 7.3.4.2.3. By End User
  • 7.3.5. United Kingdom Orthostatic Hypotension Drugs Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Diagnostics Test Type
      • 7.3.5.2.3. By End User

8. North America Orthostatic Hypotension Drugs Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Diagnostics Test Type
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United States Orthostatic Hypotension Drugs Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Diagnostics Test Type
      • 8.3.1.2.3. By End User
  • 8.3.2. Mexico Orthostatic Hypotension Drugs Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Diagnostics Test Type
      • 8.3.2.2.3. By End User
  • 8.3.3. Canada Orthostatic Hypotension Drugs Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Diagnostics Test Type
      • 8.3.3.2.3. By End User

9. South America Orthostatic Hypotension Drugs Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Diagnostics Test Type
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Orthostatic Hypotension Drugs Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Diagnostics Test Type
      • 9.3.1.2.3. By End User
  • 9.3.2. Argentina Orthostatic Hypotension Drugs Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Diagnostics Test Type
      • 9.3.2.2.3. By End User
  • 9.3.3. Colombia Orthostatic Hypotension Drugs Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Diagnostics Test Type
      • 9.3.3.2.3. By End User

10. Middle East and Africa Orthostatic Hypotension Drugs Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Diagnostics Test Type
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Orthostatic Hypotension Drugs Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Diagnostics Test Type
      • 10.3.1.2.3. By End User
  • 10.3.2. Saudi Arabia Orthostatic Hypotension Drugs Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Diagnostics Test Type
      • 10.3.2.2.3. By End User
  • 10.3.3. UAE Orthostatic Hypotension Drugs Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Diagnostics Test Type
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Orthostatic Hypotension Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

• 16.1. Mylan N.V.
  • 16.1.1. Business Overview
  • 16.1.2. Company Snapshot
  • 16.1.3. Products & Services
  • 16.1.4. Financials (In case of listed companies)
  • 16.1.5. Recent Developments
  • 16.1.6. SWOT Analysis
• 16.2. Upsher-Smith Laboratories, LLC
• 16.3. Chelsea Therapeutics International, Ltd
• 16.4. Amgen Inc
• 16.5. F. Hoffmann-La Roche Ltd
• 16.6. Apotex Inc
• 16.7. Pfizer Inc.
• 16.8. Novartis AG
• 16.9. H. Lundbeck A/S
• 16.10. Amneal Pharmaceuticals LLC

17. Strategic Recommendations

18. About Us & Disclaimer